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Introduction
Bacteria such as Escherichia coli contain efflux pumps (EP) that allow the cell to expel antibiotics into the
extracellular environment giving them the ability to be multi-drug resistant. The tri-partite complex includes
components AcrA, AcrB, and TolC. Together, they make up the efflux pump which is activated by the proton
motive force. This phenomenon has been an increasing threat to modern medicine limiting the number of
antibiotics available to treat disease. To address this issue that these efflux pumps confer on a bacterial cell, we
screened a large number of small molecules with the best potential to bind to the tripartite pump complex and
inhibit normal efflux function. Our hypothesis is that by identifying strong binding compounds to the efflux
complex, these would block small molecule efflux and restore the bacteria’s sensitivity to them.
A
Methods
E. coli Tri-partite Efflux Pump Complex. The bacterial efflux pump is comprised of a trimeric outer membrane 
spanning region (TolC), an inner membrane transporter (AcrB), and a periplasmic adaptor protein (AcrA). To drive 
antibiotics into the environment, AcrB uses energy gained from the proton motive force to move antibiotics across 
the TolC channel. 
Identifying potential efflux pump inhibitors:
1. Obtain high-quality resolution images of efflux pump components from protein 
databank found in http://www.rcsh.org
2. Identify small molecule compounds that bind to TolC docking site at 
http://zinc.docking.org/
3. Screen compounds by docking them to TolC using the following program: 
http://vina.scripps.edu/
4. Rank compounds in order of decreasing binding energies (based on intermolecular 
attractions and forces). Highly negative binding energies indicate favorable binding 
to pump.
5. Obtain promising compounds from commercial sources and run in vivo efflux assays
Measuring efflux activity in vivo:
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Virtual Screening of Potential Inhibitors Results:
• We screened 614,575 compounds from the ZINC database that had the ability to dock to the 
highly conserved TolC complex. 
• From these, 10 compounds were chosen based on:
1. Low/favorable binding energies ≤ −10.2
kcal
mol
2. Compound availability in commercial distributers
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Results
ZINC02202893
ZINC70705362
ZINC70665805
ZINC85893430
Conclusion
After virtually screening 614,575 small-molecule compounds we chose nine that proved to 
have the best potential to inhibit efflux activity based on binding energies. Accumulation 
assay trials were conducted and all of the nine compounds failed to inhibit EthBr efflux out of 
the bacterial cell. This is represented by the lack of high accumulating fluorescent levels. This 
enables us to determine that the TolC binding site is not an appropriate target for potential 
inhibitors to bind as it does not significantly affect efflux activity. In the near future we will 
work on identifying alternative binding sites along the tri-partite complex.
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